NASDAQ:ALIM - Alimera Sciences Stock Price, Forecast & News

Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM."

Alimera Sciences shares reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of Alimera Sciences stock prior to the reverse split would have 7 shares after the split.

Alimera Sciences Inc (NASDAQ:ALIM) posted its quarterly earnings results on Tuesday, October, 29th. The biopharmaceutical company reported ($0.60) EPS for the quarter, hitting analysts' consensus estimates of ($0.60). The biopharmaceutical company had revenue of $12.85 million for the quarter, compared to analysts' expectations of $12.75 million. View Alimera Sciences' Earnings History.

Alimera Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 4th 2020. View Earnings Estimates for Alimera Sciences.

Alimera Sciences updated its third quarter 2019 earnings guidance on Wednesday, October, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $12.8 million, compared to the consensus revenue estimate of $12.87 million.

3 Wall Street analysts have issued 1-year price objectives for Alimera Sciences' stock. Their forecasts range from $15.00 to $45.00. On average, they expect Alimera Sciences' share price to reach $30.00 in the next year. This suggests a possible upside of 230.0% from the stock's current price. View Analyst Price Targets for Alimera Sciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Alimera Sciences.

News stories about ALIM stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Alimera Sciences earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Alimera Sciences.

Alimera Sciences saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 996,200 shares, a decline of 29.8% from the October 31st total of 1,420,000 shares. Based on an average daily volume of 493,600 shares, the short-interest ratio is presently 2.0 days. Approximately 1.7% of the company's stock are sold short. View Alimera Sciences' Current Options Chain.

Some companies that are related to Alimera Sciences include AcelRx Pharmaceuticals (ACRX), MEI Pharma (MEIP), Fortress Biotech (FBIO), REDHILL BIOPHAR/S (RDHL), Five Prime Therapeutics (FPRX), TapImmune (MRKR), Aptinyx (APTX), Kala Pharmaceuticals (KALA), Bicycle Therapeutics (BCYC), Arbutus Biopharma (ABUS), Evelo Biosciences (EVLO), Newron Pharmaceuticals (NWPHF), Northwest Biotherapeutics (NWBO), Aldeyra Therapeutics (ALDX) and Zynerba Pharmaceuticals (ZYNE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include Eyepoint Pharmaceuticals (EYPT), NovaBay Pharmaceuticals (NBY), Agenus (AGEN), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), CorMedix (CRMD), Athersys (ATHX), BIOLINERX LTD/S (BLRX) and Cytori Therapeutics (CYTX).

Shares of ALIM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALIM stock can currently be purchased for approximately $9.09.

Alimera Sciences has a market capitalization of $45.18 million and generates $46.97 million in revenue each year. Alimera Sciences employs 124 workers across the globe.View Additional Information About Alimera Sciences.

The official website for Alimera Sciences is http://www.alimerasciences.com/.

Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The biopharmaceutical company can be reached via phone at 678-990-5740 or via email at [email protected]